-
October 11, 2016PREVIEW
In patients with stable cardiovascular (CV) disease who were taking statins, the risk of major CV events was similar in those who achieved LDL levels of 70 mg/dL or less compared with those who...
-
October 4, 2016PREVIEW
Results of a cost-effectiveness analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic...
-
July 5, 2016PREVIEW
Use of statin therapy in intermediate-risk patients without cardiovascular (CV) disease resulted in significant reductions in the risk of major CV events, according to results of the Heart...
-
May 31, 2016PREVIEW
Use of evolocumab (Repatha—Amgen) resulted in greater reductions in LDL levels compared with ezetimibe (Zetia—Merck) and was well tolerated in patients with elevated LDL levels and a history of...
-
March 14, 2016PREVIEW
Major adverse cardiovascular events (MACE) and mortality were reduced with use of statins in patients with asymptomatic peripheral arterial disease (PAD) and no signs of cardiovascular disease in...
Pages
